BRCA1 and BRCA2 mutations in a population-based study of male breast cancer

Breast Cancer Research

Paul DP Pharoah³  Douglas F Easton¹  Bruce AJ Ponder³  Simon A Gayther²  Joanna M Ward³  Julian M Lipscombe³  Victoria M Basham³ 

[1] CRC Genetic Epidemiology Group, Department of Public Health, University of Cambridge, Cambridge, UK;Institute for Cancer Genetics and Pharmacogenomics, Brunel University, Uxbridge, Middlesex, UK;CRC Human Cancer Genetics Group, Department of Oncology, University of Cambridge, Cambridge, UK

关键词: male breast cancer;    family history;    BRCA2;    BRCA1;   

Others  :  1118832
DOI  :  10.1186/bcr419

 received in 2001-08-06, accepted in 2001-10-08,  发布年份 2001

【 摘 要 】

Background

The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear.

Methods

We have carried out a population-based study of 94 MBC cases collected in the UK. We screened genomic DNA for mutations in BRCA1 and BRCA2 and used family history data from these cases to calculate the risk of breast cancer to female relatives of MBC cases. We also estimated the contribution of BRCA1 and BRCA2 to this risk.

Results

Nineteen cases (20%) reported a first-degree relative with breast cancer, of whom seven also had an affected second-degree relative. The breast cancer risk in female first-degree relatives was 2.4 times (95% confidence interval [CI] = 1.4–4.0) the risk in the general population. No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2. Allowing for a mutation detection sensitivity frequency of 70%, the carrier frequency for BRCA2 mutations was 8% (95% CI = 3–19). All the mutation carriers had a family history of breast, ovarian, prostate or pancreatic cancer. However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives.

Conclusion

These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found.

【 授权许可】

   
2002 Basham et al., licensee BioMed Central Ltd

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Casagrande JT, Hanisch R, Pike MC, Ross RK, Brown JB, Henderson BE: A case-control study of male breast cancer. Cancer Res 1988, 48:1326-1330.
• [2]Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF, Isacson P, Greenberg RS, Key C, Kolonlel L, West D: Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 1991, 83:849-854.
• [3]Anderson DE, Badzioch MD: Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992, 84:1114-1117.
• [4]Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH: A systematic population based assessment of cancer risk in first degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1608.
• [5]Storm HH, Olsen J: Risk of breast cancer in offspring of male breast-cancer patients [letter]. Lancet 1999, 353:209.
• [6]Hemminki K, Vaittinen P: Male breast cancer: risk to daughters. Lancet 1999, 353:1186-1187.
• [7]Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001, 68:410-419.
• [8]Couch FJ, Farid LM, Deshano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck Eidens D, Godwin A, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL: BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996, 13:123-125.
• [9]Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord J: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996, 13:117-119.
• [10]Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton Culver H: Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997, 60:313-319.
• [11]Mavraki E, Gray IC, Bishop DT, Spurr NK: Germline BRCA2 mutations in men with breast cancer. Br J Cancer 1997, 76:1428-1431.
• [12]Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A: BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998, 58:1367-1371.
• [13]Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B, Olah E: High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999, 59:995-998.
• [14]Kwiatkowska E, Teresiak M, Lamperska KM, Karczewska A, Breborowicz D, Stawicka M, Godlewski D, Krzyzosiak WJ, Mackiewicz A: BRCA2 germline mutations in male breast cancer patients in the Polish population [letter]. Hum Mutat 2001, 17:73.
• [15]Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J: Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 1999, 65:1800-1802.
• [16]Sverdlov RS, Barshack I, Bar Sade RB, Baruch RG, Hirsh Yehezkel G, Dagan E, Feinmesser M, Figer A, Friedman E: Genetic analyses of male breast cancer in Israel. Genet Test 2000, 4:313-317.
• [17]Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS, Tucker MA: Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995, 57:1-7.
• [18]Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R, Friedman LS, King MC, Egilsson V, Devilee P, McManus R, Daly PA, Smyth E, Ponder BAJ, Peto J, Cannon-Albright L, Easton DF, Goldgar DE: Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994, 7:103-107.
• [19]Coleman M, Douglas A, Hermon C, Peto J: Cohort study analysis with a FORTRAN computer program. Int J Epidemiol 1986, 15:134-137.
• [20]Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D, Clayton C, Stratton MR, Ponder BAJ: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation. Nat Genet 1995, 11:428-433.
• [21]Breast Information Core Database [http:/ / www.nhgri.nih.gov/ Intra-mural_research/ Lab_transfer/ Bic/ Member/ index.html] webcite
• [22]Kerber RA, Slattery ML: Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997, 146:244-248.
• [23]Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkadottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayhter SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Hedman MZ, Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689.
• [24]Robson M: Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. J Clin Oncol 2000, 18(suppl):113s-118s.
• [25]Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C, Meijers Heijboer EJ, Klijn JG: Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 2000, 18(suppl):119s-124s.